Long-Term Effects of Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Body Composition and Bone Mass Density

BackgroundCurrently, the two most common bariatric procedures are laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB). Long-term data comparing the two interventions in terms of their effect on body composition and bone mass density (BMD) are scarce.ObjectiveThe aim of this study was to assess body composition and BMD at least 5 years after LSG and LRYGB.SettingDepartment of Endocrinology and Nutrition, St. Claraspital Basel and St. Clara Research Ltd., Basel, Switzerland.MethodsBariatric patients at least 5 years after surgery (LSG or LRYGB) were recruited, and body composition and BMD were measured by means of dual-energy X-ray absorptiometry. Data from body composition before surgery were included in the analysis. Blood samples were taken for determination of plasma calcium, parathyroid hormone, vitamin D₃, alkaline phosphatase, and C-terminal telopeptide, and the individual risk for osteoporotic fracture assessed by the Fracture Risk Assessment Tool score was calculated. After surgery, all patients received multivitamins, vitamin D₃, and zinc. In addition, LRYGB patients were prescribed calcium.ResultsA total of 142 patients were included, 72 LSG and 70 LRYGB, before surgery: median body mass index 43.1, median age 45.5 years, 62.7% females. Follow-up after a median of 6.7 years. For LRYGB, the percentage total weight loss at follow-up was 26.3% and for LSG 24.1% (p = 0.243). LRYGB led to a slightly lower fat percentage in body composition. At follow-up, 45% of both groups had a T score at the femoral neck below −1, indicating osteopenia. No clinically relevant difference in BMD was found between the groups.ConclusionsAt 6.7 years after surgery, no difference in body composition and BMD between LRYGB and LSG was found. Deficiencies and bone loss remain an issue after both interventions and should be monitored.     

En Bloc Excision of Phyllodes Tumor of the Breast: Radical Approach Heralds Better Outcome

IntroductionSurgery is the primary treatment of phyllodes tumor of the breast, and margins are the most important risk factor associated with local recurrence. We conducted a retrospective audit of 433 patients treated at our center.Patients and MethodsWomen who presented with phyllodes tumors between 1999 and 2017 were included in the analysis. Data was collected from the hospital medical records, telephonic interviews, and electronic mail.ResultsOf the 433 women included in this study, 177 (40.9%) had benign phyllodes tumors, 84 (19.4%) were borderline, 131 (30.3%) were malignant, and 41 (9.5%) had sarcoma. A history of previous excision was noted in 154 (35.6%) patients, of which 104 presented with local recurrence. Of the total patients, 209 (48.3%) underwent breast conservation surgery; the median pT was 6 cm. At a median follow-up of 37.9 months, the 5-year disease-free survival (DFS) was 82.9%. On multivariate analysis, the factors that impacted DFS were histology (hazard ratio, 4.1; 95% confidence interval [CI], 1.5-10.9; P = .005) and history of previous excision biopsy (hazard ratio, 3.39; 95% CI, 1.76-6.52; P < .001). We analyzed 231 women who presented without any prior excision separately, wherein at a median follow-up of 44.1 months, the DFS was 92.1% (95% CI, 92.05%-92.15%). In addition, less recurrences were noted in this cohort (5.6% [13/231] in no-excision biopsy vs. 12.5% with surgery done prior to presentation to our institute).ConclusionA previous history of excision and the histologic subtype of phyllodes tumor are factors that have an impact on DFS, thus emphasizing the need for appropriate surgical planning and en bloc excision of the phyllodes at presentation.     

胸神经联合前锯肌平面阻滞对保留胸肌乳腺癌根治术后患者早期康复质量的影响

目的 探索胸神经联合前锯肌平面阻滞对保留胸肌乳腺癌根治术后患者早期恢复质量的影响。方法 选取2020年9月～2021年3月在邯郸市中心医院诊断乳腺癌并拟行保留胸肌式乳腺癌根治术的117例患者。根据是否术前行胸神经联合阻滞，分为全麻组和全麻复合神经阻滞组。于术毕24、48 h记录患者恶心呕吐发生率，上肢感觉异常，腋窝疼痛评分以及镇痛补救药物的用量。术毕48 h，行40项恢复质量评分量表（QoR 40）评分。比较术前血常规与术后一天血常规中性粒细胞和淋巴细胞的比值。结果 全麻复合神经阻滞组在24、48 h的恶心呕吐发生率及镇痛补救药物用量均显著低于全麻组（P＜0.05），术毕24 h的上肢感觉异常，腋窝疼痛评分全麻复合神经阻滞组均显著低于全麻组（P＜0.05），术后QoR-40评分全麻复合神经阻滞组显著高于全麻组（P＜0.05）。术后中性粒细胞和淋巴细胞的比值全麻复合神经阻滞组较全麻组明显降低（P＜0.05）。结论 全麻复合胸神经阻滞可提高保留胸肌式乳腺癌根治术后患者的舒适度和满意度，有助于提高早期康复的质量。     

Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives

Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have always been considered rare tumors, their incidence has risen over the past few decades. They represent a highly heterogeneous group of neoplasms with several prognostic factors, including disease stage, proliferative index (Ki67), and tumor differentiation. Most of these neoplasms express somatostatin receptors on the cell surface, a feature that has important implications in terms of prognosis, diagnosis, and therapy. Although International Guidelines propose algorithms aimed at guiding therapeutic strategies, GEP-NEN patients are still very different from one another, and the need for personalized treatment continues to increase. Radical surgery is always the best option when feasible; however, up to 80% of cases are metastatic upon diagnosis. Regarding medical treatments, as GEP-NENs are characterized by relatively long overall survival, multiple therapy lines are adopted during the lifetime of these patients, but the optimum sequence to be followed has never been clearly defined. Furthermore, although new molecular markers aimed at predicting the response to therapy, as well as prognostic scores, are currently being studied, their application is still far from being part of daily clinical practice. As they represent a complex disease, with therapeutic protocols that are not completely standardized, GEP-NENs require a multidisciplinary approach. This review will provide an overview of the available therapeutic options for GEP-NENs and attempts to clarify the possible approaches for the management of these patients and to discuss future perspectives in this field.     

De novo hiatal hernia of the gastric tube after sleeve gastrectomy

IntroductionSleeve gastrectomy (SG) is a frequently used surgical procedure for the treatment of morbid obesity. Several complications of SG have been described; however, de novo hiatal hernia of the gastric tube, as a complication of SG, has not been described in the literature.Presentation of caseHere, we report a case of a hiatal hernia 2 years after SG. In the case reported here, the hiatal hernia was associated with weight regain. The mechanisms responsible for the herniation of the pouch are difficult to identify. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass is an effective treatment for this complication. Its management is safe and effective.DiscussionObesity itself is an independent risk factor for hiatal hernia, found preoperatively in more than half of the morbidly obese patients. This predisposition is explained by higher intra-gastric pressure due to intra-abdominal or visceral fat, reduced inferior oesophageal sphincter pressure, and oesophageal motility problems.ConclusionTo our knowledge, this is the first described case of hiatal hernia of the gastric tube after SG.     

食管癌术后发生急性肾损伤危险因素分析及处理

目的探讨食管癌术后急性肾损伤(acute kidney injury,AKI)的危险因素、临床意义及围手术期处理。方法回顾性分析397例食管癌手术患者的临床资料,统计术后AKI的发生情况,按有无AKI发生分为AKI组和非AKI组,将发生AKI患者与非AKI患者进行相关因素比较分析。结果本组研究397例食管癌手术患者中25例发生AKI,其中Ⅰ期15例,Ⅱ期4例,Ⅲ期6例,总患病率为6.3%。25例发生AKI的患者中,出院时存活21例(占84%),死亡4例(占16%)。AKI与非AKI的相关因素比较:年龄、冠心病、慢性阻塞性肺疾病、术前血肌酐、术前化疗、淋巴结清扫数、术中失血量、手术时间、术后呼吸机应用时间等因素差异,无统计学意义(P0.05);糖尿病、高血压、术后肺部感染及肾外器官衰竭差异有统计学意义(P0.05)。Logistic多因素回归分析结果显示,糖尿病、高血压、术后肺部感染及肾外器官衰竭是食管癌术后并发AKI的独立危险因素。结论 AKI是食管癌患者术后常见的并发症且易被忽视,须注意引起AKI的常见原因,对于存在AKI危险因素的患者加强围手术期管理,严密监测肾功能。一旦发生AKI,预后极差,因此,要早期选择最佳的治疗方案,提高食管癌患者术后生存率,减少病死率。     

Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients

ObjectiveTo test the expandability of active surveillance (AS) to Gleason score 3+4 cancers by assessing the unfavorable disease risk in a large multi-institutional cohort.Materials and methodsWe performed a retrospective analysis including 2,323 patients with localized Gleason score 3+4 prostate cancer who underwent a radical prostatectomy between 2005 and 2013 from 6 academic centers. We analyzed the rates of biopsy downgrading/upgrading and advanced stage in the overall cohort by employing standardized AS criteria (using biopsy Gleason score 3+4).ResultsThe final pathologic Gleason score was 3+3 = 6 in 8%, 3+4 = 7 in 67%, 4+3 = 7 in 20%, and 8 to 10 in 5% cases. The overall rate of unfavorable disease (upgrading or advanced stage or both) was 46%. In multivariable analysis, prostate-specific antigen (PSA) level>10 ng/ml, PSA density (PSAD) >0.15 ng/ml/g, clinical stage >T1, and>2 positive cores were predictors of unfavorable disease. According to the AS criteria used, the risk of unfavorable disease ranged from 30% to 42%. In patients without any risk factor (PSA level≤10 ng/ml, PSAD ≤0.15 ng/ml/g, T1c, and≤2 positive cores), the unfavorable disease rate was 19%. The main limitations of this study are the retrospective design and nonstandardization of pathologic assessment between centers.ConclusionsApproximately half of patients with biopsy Gleason score 3+4 cancer have unfavorable disease at final pathology. Nevertheless, expanding AS eligibility to these patients may be acceptable provided adherence to strict selection criteria leading to a<20% risk of unfavorable disease. Future tools for selection such as magnetic resonance imaging, early rebiopsy, and serum markers may be especially beneficial in this group of patients.